Breaking News
November 16, 2018 - Many RA patients’ pain related to central nervous system
November 16, 2018 - Changes in Himalayan gut microbiomes linked to diet
November 16, 2018 - Inhibition of prostaglandin E2 enhances ability to combat infectious colitis
November 16, 2018 - Chronic dry eye can slow reading rate and disrupt day to day tasks
November 16, 2018 - Researchers develop new drug molecule that inhibits inflammation
November 16, 2018 - Dementia symptoms peak in winter and spring, study finds
November 16, 2018 - Stanford tobacco researcher weighs in on JUUL
November 16, 2018 - Increasing omega-3 fatty acid intake during pregnancy reduces risk of premature birth, review finds
November 16, 2018 - Researchers find no link between infants waking up at night and later developmental problems
November 16, 2018 - Both parents and children agree about confidential medical services
November 16, 2018 - FDA warns against use of unapproved pain medications with implanted pumps
November 16, 2018 - Precision medicine-based approach to slow or reverse biologic drivers of Alzheimer’s disease
November 16, 2018 - Study provides new insight into norovirus outbreaks, may help guide efforts to develop vaccines
November 16, 2018 - Inexpensive, portable air purifier could help protect the heart from pollution
November 16, 2018 - New 15-minute scan could help diagnose brain damage in babies up to two years old
November 16, 2018 - Deep brain stimulation not effective for treating early Alzheimer’s
November 16, 2018 - Traditional chemotherapy superior to new alternative for oropharyngeal cancers | News Center
November 16, 2018 - What This Pond Protist Does With Its Genome Will Astound You
November 15, 2018 - Researchers develop tool that speeds up analysis and publication of biomedical data
November 15, 2018 - Scientists identify mechanism used by lung cancer cells to obtain glucose
November 15, 2018 - Abnormalities in development of the brain could be involved in onset of autism, finds new study
November 15, 2018 - Soy protein equally effective as animal protein in building muscle strength
November 15, 2018 - American Academy of Pediatrics, Nov. 2-6
November 15, 2018 - Dopamine drives early addiction to heroin
November 15, 2018 - Variance in gut microbiome in Himalayan populations linked to dietary lifestyle | News Center
November 15, 2018 - Reducing Cardiovascular Disease: The Amish Way
November 15, 2018 - King’s researchers launch charter to guide organizations to engage abuse survivors in research
November 15, 2018 - Enable Injections enters into development agreements with UCB and Apellis Pharmaceuticals
November 15, 2018 - TGen North collaborates with NARBHA Institute to advance human health
November 15, 2018 - Researchers discover molecular basis for therapeutic actions of an African folk medicine
November 15, 2018 - Human Cell Atlas study of early pregnancy shows how mother’s immune system is modified
November 15, 2018 - New guidelines for detecting and managing sarcopenia to be launched in the UK
November 15, 2018 - Researchers explore role of dietary composition on energy expenditure
November 15, 2018 - Elsevier launches Entellect™ Platform, unlocking value by creating AI-ready life sciences data
November 15, 2018 - Now that cannabis is legal in Canada, let’s use it to tackle the opioid crisis
November 15, 2018 - In the Spotlight: At the intersection of tech, health, and ethics
November 15, 2018 - Traditional Glaucoma Test Can Miss Severity of the Disease
November 15, 2018 - Researchers directly connect activities of genes with instinctive behavior in male cichlids
November 15, 2018 - Salk researchers report new methods to identify AD drug candidates with anti-aging properties
November 15, 2018 - St. Jude Hospital announces availability of largest collections of leukemia samples
November 15, 2018 - Attenua Announces First Patient Treated in Phase 2 Clinical Trial in Chronic Cough with Bradanicline
November 15, 2018 - Designing a novel cell-permeable peptide chimera to promote wound healing
November 15, 2018 - NEI investigators combine two imaging modalities to view the retina in unprecedented detail
November 15, 2018 - Determining how hearts develop to better understand congenital heart defects
November 15, 2018 - Maverick immune cells can act independently to identify and kill cancer cells, finds research
November 15, 2018 - Advanced AI and big data methods to tackle dementia
November 15, 2018 - Report reveals increase in pancreatic cancer death rates across Europe
November 15, 2018 - Luxia Scientific announces availability of its gut microbiome test in Luxembourg
November 15, 2018 - New diabetes drugs linked to increased risk of lower-limb amputation and ketoacidosis
November 15, 2018 - New approach targets matrix surrounding neurons to protect neurons after stroke
November 15, 2018 - Lilly Submits New Drug Application to the FDA for Lasmiditan for Acute Treatment of Migraine
November 15, 2018 - Heart failure patients shouldn’t stop meds even if condition improves: study
November 15, 2018 - Parents and carers of people with diabetes experience emotional or mental health problems
November 15, 2018 - RetiPharma secures funding to develop new peptide drug for treating degenerative eye disorders
November 15, 2018 - Breakthrough research could lead to a new wave of cancer-fighting antibodies
November 15, 2018 - Mylan and Biocon launch new insulin glargine biosimilar in the UK
November 15, 2018 - For wildfire safety, only particular masks guard against toxic particulate matter
November 15, 2018 - New study of tribe shows influence of Western diet and lifestyle on blood pressure
November 15, 2018 - Scientists harness power of natural killer cells to treat children with neuroblastoma
November 15, 2018 - Investigating foodborne disease outbreak in Bosnia and Herzegovina based on simulation game
November 15, 2018 - Recommendations Issued for Management of Bradycardia
November 15, 2018 - Benefit unclear due to a lack of suitable studies
November 15, 2018 - TAMEST recognizes UT Southwestern’s Ralph DeBerardinis for changing our understanding of cancer
November 15, 2018 - Researchers discover key factors behind intestinal inflammation in CVID patients
November 15, 2018 - CityU develops first microarrayed 3D neuronal culture platform
November 15, 2018 - Expert suggests ways to control uncomfortable vaginal symptoms in diabetic women
November 15, 2018 - New edition of Red Journal focuses on roles of imaging in radiation oncology
November 15, 2018 - Doctors Aren’t Promoting Breastfeeding’s Cancer-Protection Benefit
November 15, 2018 - Collection of demonstration projects highlights value of patient engagement in research
November 15, 2018 - Technique to ‘listen’ to a patient’s brain during tumour surgery
November 15, 2018 - Seven-year-old returns to life as a “normal, healthy child” following bone marrow transplant
November 15, 2018 - AMSBIO expands range of high quality FFPE cancer cell line controls
November 15, 2018 - Marijuana use by kidney donors has no effect on transplant outcomes
November 15, 2018 - Exploring NMR Spectroscopy Applications through Interesting Infographics
November 15, 2018 - Chapman University wins additional $2.9 million NIH grant to study Alzheimer’s disease
November 15, 2018 - Microgel powder reduces infection and promotes healing
November 15, 2018 - Suicidal patients with prescribed access to psychotropic drugs should be closely monitored
November 15, 2018 - Nitric oxide-releasing technology shows potential to reduce healing time of diabetic foot ulcers
November 15, 2018 - Mass shootings may trigger unnecessary blood donations
November 15, 2018 - From heart disease to cancer: New study tracks shift of county death rates
Anti-integrin therapy effect on intestinal immune system in HIV-infected patients

Anti-integrin therapy effect on intestinal immune system in HIV-infected patients

image_pdfDownload PDFimage_print
The researchers’ anti-integrin therapy using the approved medication vedolizumab (VDZ) reduced aggregates of immune cells (green) in intestinal biopsies from a patient with HIV and IBD. Credit: M. Uzzan et al., Science Translational Medicine (2018)

In a study published today in Science Translational Medicine, Mount Sinai researchers describe for the first time a mechanism that may shrink collections of immune cells in the gastrointestinal (GI) tract, called lymphoid aggregates, where HIV may lay sequestered. These findings may be of interest to scientists who are involved in researching the cure for HIV infection in light of the strong role that the intestines play in it.

The study builds on research by the same team which found in 2004 that the intestines are specifically targeted by HIV at the earliest stage of infection. “We know from our earlier research that intestinal immune cells called CD4+ T cells are profoundly depleted during the earliest stages of HIV infection. Newer research from other groups has found that CD4 + T cells that migrate to the gut, and bear a receptor called a4b7, are highly susceptible to HIV,” says Saurabh Mehandru, MD, Associate Professor of Medicine (Gastroenterology) at the Icahn School of Medicine at Mount Sinai and the senior author on this study. Dr. Mehandru directs an immunology lab, part of the Division of Gastroenterology at the Icahn School of Medicine. The Mehandru Lab studies mucosal immunology as it pertains to immune deficiency states such as HIV infection and inflammatory disorders, with inflammatory bowel disease (IBD) being a focal point.

“Now, 14 years later, we have discovered how anti-a4b7 therapy can significantly, and rather unexpectedly, lead to the attenuation of lymphoid aggregates,” continues Dr. Mehandru. This is the first report of reduction in GI-associated lymphoid aggregates by a therapeutic intervention in patients with HIV-1 infection. “As such, these data describe a new mechanism of action of treatments targeting the a4b7 receptor and define a rational basis for the use of these treatments in HIV-1 infection and beyond,” says Dr. Mehandru.

Study authors, led by Ph.D. student Mathieu Uzzan, designed a study that involved a cohort of six individuals with mild IBD and concomitant HIV-1 infection receiving anti-a4b7 treatment, specifically vedolizumab (VDZ). VDZ has become a frontline strategy in the management of patients with IBD, in whom it has demonstrated strong efficacy and an excellent safety profile. The investigators studied immune cells in the blood and the intestines and describe the immunological and virological effects of VDZ therapy over a 30-week period.

“The therapy was tolerated well, with only minor adverse events reported. We were surprised by the impact of treatment on lymphoid aggregates in the GI tract of patients with HIV-1 infection. We believe these initial findings could have significant implications for HIV-1 infection, perhaps in combination with other agents such as broadly neutralizing anti-HIV antibodies,” says Dr. Mehandru.

Research was facilitated by scientists at the University of Hawaii, the Wistar Institute, the University of Montreal, and the University of Minnesota.


Explore further:
Protein produced in gut could stave off deadly bone marrow transplant complication

More information:
M. Uzzan el al., “Anti-a4ß7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1–infected individuals,” Science Translational Medicine (2018). stm.sciencemag.org/lookup/doi/ … scitranslmed.aau4711

Journal reference:
Science Translational Medicine

Provided by:
The Mount Sinai Hospital

Tagged with:

About author

Related Articles